pD2 values and Emax to phenylephrine in saphenous rings in control and experimental conditions
| Phenylephrine . | n . | pD2 . | Emax . |
|---|---|---|---|
| Control | 15 | 6.03 ± 0.13 | 152 ± 8 |
| Ranolazine 10−6 M | 5 | 6.22 ± 0.11 | 146 ± 10 |
| Ranolazine 10−5 M | 14 | 5.31 ± 0.23* | 139 ± 7 |
| Ranolazine 10−4 M | 5 | 5.17 ± 0.26* | 110 ± 4* |
| Ranolazine 10−5 M + indomethacin 10−5 M | 5 | 4.93 ± 0.20 | 139 ± 11 |
| Ranolazine 10−5 M + l-NAME 10−4 M | 5 | 5.34 ± 0.20 | 138 ± 2 |
| Ranolazine 10−5 M + TEA 10−3 M | 5 | 5.74 ± 0.09 | 146 ± 4 |
| Ranolazine 10−5 M + charybdotoxin 10−7 M | 7 | 5.61 ± 0.23 | 159 ± 11 |
| Ranolazine 10−5 M + TRAM-34 10−6 M | 5 | 5.23 ± 0.24 | 138 ± 13 |
| Ranolazine 10−5 M + apamin 10−6 M | 5 | 5.35 ± 0.39 | 133 ± 5 |
| Phenylephrine . | n . | pD2 . | Emax . |
|---|---|---|---|
| Control | 15 | 6.03 ± 0.13 | 152 ± 8 |
| Ranolazine 10−6 M | 5 | 6.22 ± 0.11 | 146 ± 10 |
| Ranolazine 10−5 M | 14 | 5.31 ± 0.23* | 139 ± 7 |
| Ranolazine 10−4 M | 5 | 5.17 ± 0.26* | 110 ± 4* |
| Ranolazine 10−5 M + indomethacin 10−5 M | 5 | 4.93 ± 0.20 | 139 ± 11 |
| Ranolazine 10−5 M + l-NAME 10−4 M | 5 | 5.34 ± 0.20 | 138 ± 2 |
| Ranolazine 10−5 M + TEA 10−3 M | 5 | 5.74 ± 0.09 | 146 ± 4 |
| Ranolazine 10−5 M + charybdotoxin 10−7 M | 7 | 5.61 ± 0.23 | 159 ± 11 |
| Ranolazine 10−5 M + TRAM-34 10−6 M | 5 | 5.23 ± 0.24 | 138 ± 13 |
| Ranolazine 10−5 M + apamin 10−6 M | 5 | 5.35 ± 0.39 | 133 ± 5 |
Data are shown as mean ± SEM. Emax are expressed as a percentage of response to 60 mM KCl.
P < 0.05 versus control.
Emax: maximum effect; l-NAME: NG-nitro-l-arginine methyl ester; n: number of patients; pD2: −log EC50; SEM: standard error of mean; TEA: tetraethylammonium.
pD2 values and Emax to phenylephrine in saphenous rings in control and experimental conditions
| Phenylephrine . | n . | pD2 . | Emax . |
|---|---|---|---|
| Control | 15 | 6.03 ± 0.13 | 152 ± 8 |
| Ranolazine 10−6 M | 5 | 6.22 ± 0.11 | 146 ± 10 |
| Ranolazine 10−5 M | 14 | 5.31 ± 0.23* | 139 ± 7 |
| Ranolazine 10−4 M | 5 | 5.17 ± 0.26* | 110 ± 4* |
| Ranolazine 10−5 M + indomethacin 10−5 M | 5 | 4.93 ± 0.20 | 139 ± 11 |
| Ranolazine 10−5 M + l-NAME 10−4 M | 5 | 5.34 ± 0.20 | 138 ± 2 |
| Ranolazine 10−5 M + TEA 10−3 M | 5 | 5.74 ± 0.09 | 146 ± 4 |
| Ranolazine 10−5 M + charybdotoxin 10−7 M | 7 | 5.61 ± 0.23 | 159 ± 11 |
| Ranolazine 10−5 M + TRAM-34 10−6 M | 5 | 5.23 ± 0.24 | 138 ± 13 |
| Ranolazine 10−5 M + apamin 10−6 M | 5 | 5.35 ± 0.39 | 133 ± 5 |
| Phenylephrine . | n . | pD2 . | Emax . |
|---|---|---|---|
| Control | 15 | 6.03 ± 0.13 | 152 ± 8 |
| Ranolazine 10−6 M | 5 | 6.22 ± 0.11 | 146 ± 10 |
| Ranolazine 10−5 M | 14 | 5.31 ± 0.23* | 139 ± 7 |
| Ranolazine 10−4 M | 5 | 5.17 ± 0.26* | 110 ± 4* |
| Ranolazine 10−5 M + indomethacin 10−5 M | 5 | 4.93 ± 0.20 | 139 ± 11 |
| Ranolazine 10−5 M + l-NAME 10−4 M | 5 | 5.34 ± 0.20 | 138 ± 2 |
| Ranolazine 10−5 M + TEA 10−3 M | 5 | 5.74 ± 0.09 | 146 ± 4 |
| Ranolazine 10−5 M + charybdotoxin 10−7 M | 7 | 5.61 ± 0.23 | 159 ± 11 |
| Ranolazine 10−5 M + TRAM-34 10−6 M | 5 | 5.23 ± 0.24 | 138 ± 13 |
| Ranolazine 10−5 M + apamin 10−6 M | 5 | 5.35 ± 0.39 | 133 ± 5 |
Data are shown as mean ± SEM. Emax are expressed as a percentage of response to 60 mM KCl.
P < 0.05 versus control.
Emax: maximum effect; l-NAME: NG-nitro-l-arginine methyl ester; n: number of patients; pD2: −log EC50; SEM: standard error of mean; TEA: tetraethylammonium.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
